Rotator Cuff TearsNCT05453266
Arthroscopic Rotator Cuff Repair Performed With Intraarticular Tranexamic Acid Could it Provide Improved Visual Clarity and Less Post-operative Pain? A Prospective, Double Blind, Randomized Study of 64 Patients.
A study testing Application of Tranexamic acid in arthroscopic irrigation solution and No application of Tranexamic acid in arthroscopic irrigation solution in people with Rotator Cuff Tears and Rotator Cuff Rupture, run by Florence Nightingale Hospital, Istanbul at 1 site in Turkey (Türkiye).
Trial summary
Shoulder arthroscopy is widely used for treatment of different shoulder pathologies. Visual clarity is essential for successful and safe surgery. The aim of present study is to determine whether intraarticular use of tranexamic acid (TXA) in surgery fluid can improve visual clarity and early postoperative pain. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Rotator Cuff Tears, Rotator Cuff Rupture, Tranexamic Acid
- What is being tested?
- Application of Tranexamic acid in arthroscopic irrigation solution and No application of Tranexamic acid in arthroscopic irrigation solution
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 63 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2022to 10 Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- being older than 18 years of age,
- having an MRI confirmed rotator cuff rupture with a history of failure of conservative treatment of at least 6 months,
- being willing to participate to the clinical trial.
Who cannot join
- patients with a history of coagulopathy, deep venous thrombosis, tendency to thrombotic events,
- patients under anti-coagulant therapy,
- patients with inferior vena cava filter,
- patients with abnormal prothrombin time-activated partial thromboplastin time-bleeding time,
- patients with a history of cardiac/renal/hepatic disease,
- patients with a diagnosis of TXA allergy,
- patients with an acute RCT, having been treated conservatively for less than 6 months,
- being under the age of 18
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Arthroscopic Rotator Cuff Repair Performed With Intraarticular Tranexamic Acid. Could it Provide Improved Visual Clarity and Less Post-operative Pain? A Prospective, Double Blind, Randomized Study of 63 Patients
Shoulder arthroscopy is widely used for treatment of different shoulder pathologies. Visual clarity is essential for successful and safe surgery. The aim of present study is to determine whether intraarticular use of tranexamic acid (TXA) in surgery fluid can improve visual clarity and early postoperative pain.
Read the detailed description
Patients and Methods After obtaining institutional review board approval (Istanbul Yeni Yuzyil University, Nr: 13.02.2020/009) together with the registry to ClinicalTrials.gov, patients were prospective enrolled in this observational study, which was designed as double-blind, placebo-controlled and randomized.
Inclusion criteria were defined as: being older than 18 years of age, having an MRI confirmed rotator cuff rupture with a history of failure of conservative treatment of at least 6 months, being willing to participate to the clinical trial.
Patient Selection Exclusion criteria were defined as: patients with a history of coagulopathy, deep venous thrombosis, tendency to thrombotic events, patients under anti-coagulant therapy, patients with inferior vena cava filter, patients with abnormal prothrombin time-activated partial thromboplastin time-bleeding time, patients with a history of cardiac/renal/hepatic disease, patients with a diagnosis of TXA allergy, patients with an acute RCT, having been treated conservatively for less than 6 months, being under the age of 18. Table 1.
As a result of the inclusion/exclusion criteria, 42 patients (14 had acute RCT, 12 were receiving anti-coagulant therapy, 9 had history of cardiac/hepatic/renal disease, 5 had abnormal PT-aPTT value at the time of the diagnosis, 2 had received conservative treatments for less than 6 months for RCR) were excluded from 105 patients, who were eligible and were willing to participate. The remaining 63 patients were enrolled in the study. Table 2 (Flowchart). All patients provided informed consents, so that their pre-operative, intra-operative and post-operative data including imaging studies and arthroscopic images could be used for publication by concealing their identity.
Randomization By using computer based randomization software acquired from random.org, patients were randomized into two groups comprising a TXA group (n=32, 24M, 8F) (TXA Group) and a control group (n=31, 22M,9F) (Control Group), while group information was neither shared with patients nor with the operating surgeon as a result of double-blind nature of the study.
Double-blinded preparation of the Irrigation Solutions To conduct a double-blinded, randomized control study, arthroscopic irrigation solutions (normal saline) of 3 liters were prepared by an operating nurse, while 250 mg TXA was injected into irrigation solutions of Group 1, and irrigation solutions of Group 2 were left TXA-free without any injection.
Surgical Procedures All procedures were performed under general anesthesia in beach-chair position by the same surgeon (C.B.) by following the exact same surgical steps in the exact same sequence irrespective of the patient's assignment to TXA group or control group. The surgical procedure comprised thorough evaluation of the glenohumeral joint, together with the rotator interval. In case of a degenerative biceps tendon, a biceps tenotomy was undertaken (TXA Group: 28 patients, Control Group: 26 patients). The repair of supraspinatus tendon was undertaken by utilizing single-row technique. A pressure-controlled pump was used to keep the pressure of the irrigation solution constantly at 50 mmHg. When visibility was decreased as a result of hemorrhage, the pressure was increased by 20 mmHg by using the flush option of the device. During the operation, mean arterial pressure was recorded by the anesthesiologist.
Assessment of Intra-Operative Arthroscopic Visual Clarity and Secondary Outcome Parameters Single surgeon (CB) rated arthroscopic visual score (AVS) similar to the grading system used by van Montfoort21 was used to evaluate intra-operative clarity. AVS was composed of five grades: Grade I: I had no disruption of visual clarity due to bleeding.
Grade II: I had mild disruption of visual clarity due to bleeding. Grade III: I had moderate disruption of visual clarity due to bleeding. Grade IV: I had severe disruption of visual clarity due to bleeding. Grade V: As a result of extreme disruption of visual clarity due to bleeding, I had to convert to open surgery.
AVS score for every patient was calculated as the following: The video of the operation was watched by the operating surgeon (CB) after the surgery and at every 15 minutes, a score of AVS was recorded. At the end, the average score for every single patient was calculated.
Pain was evaluated by using visual analogue scale (VAS) post-operative 8th, 24th and 48th hour.
Patients' mean arterial pressures (MAP) and total duration of operations were recorded.
All of the average aforementioned data of the two groups were compared. Post-operative Patient Management Patients were applied abduction brace after the operation and they were advised to limit the active shoulder range of motion together with abduction during their stay in the hospital.
Pain management was performed by 500 mg paracetamol injection at every 8 hours and intramuscular injection of ketorolac at 24 hours. Patients were discharged at the second post-operative day, when they were confirmed to be stable with tolerable pain.
Statistical method To calculate the sample size, G-Power software (gpower.hhu.de, v 3.1.9.4) was used, while a statistical power (1-ß), alpha error and impact value were calculated as 0.8, 0.05 and 0.8 respectively. As a result of this priori power analysis model, at least 30 speciments were calculated to be required in each group, which was consistent with out design.
For the statistical analysis SPSS software (Version 25.0; SPSS Inc, Chicago, IL, USA) was used. Data are expressed as mean +/- SD (standard deviation). The cohort and the variables were tested for normal distribution and data normality was confirmed by Shapiro-Wilk test. Age, sex, surgery time, mean arterial blood pressure, surgical visaualization score, AVS and postoperative pain scores were compared between groups. Demographic characteristics of the patients were analyzed using descriptive statistics analysis methods, with mean and standard deviation. Normality analysis was made with different methods including histogram, kurtosis and skewness test. Independent sample t-test was used to compare the difference between groups. Analysis of postoperative pain scores at different time points scores within the groups at different time points was made with repeated measures ANOVA test. Results were reported at a 95% confidence interval, and P values <0.05 were considered statistically significant.
- Conditions
- Rotator Cuff Tears, Rotator Cuff Rupture, Tranexamic Acid, Shoulder Arthroscopy, Visual Clarity
- Being tested
- Application of Tranexamic acid in arthroscopic irrigation solution, No application of Tranexamic acid in arthroscopic irrigation solution
- Keywords
- Rotator cuff tear, Rotator cuff rupture, Tranexamic acid, Shoulder arthroscopy, Visual clarity
- Medical subject headings
- Rotator Cuff Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Application of Tranexamic acid in arthroscopic irrigation solutionProcedure or surgery
Application of Tranexamic acid in arthroscopic irrigation solution
No application of Tranexamic acid in arthroscopic irrigation solutionProcedure or surgery
No application of Tranexamic acid in arthroscopic irrigation solution
| Study group | Role | What they receive |
|---|---|---|
| TXA Group | Active comparator | Patients with rotator cuff tear, operated arthroscopically under intraarticularly applied tranexamic acid in arthroscopic irrigation solution. Receives: Procedure: Application of Tranexamic acid in arthroscopic irrigation solution |
| Control group | Placebo comparator | Patients with rotator cuff tear, operated arthroscopically without intraarticularly applied tranexamic acid in arthroscopic irrigation solution. Receives: Procedure: No application of Tranexamic acid in arthroscopic irrigation solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Arthroscopic Visual Clarity
Effect of TXA in arthroscopic irrigation solution to Arthroscopic Visual Clarity
Measured: Intra-operatively
Secondary outcomes (1)
Post-operative Pain Evaluation
Visual Analog Scale (VAS)
Measured: Up to the 2nd post-operative day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2022
- Study start1 Jan 2022
- Primary completion5 Jun 2022
- Study completion10 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rotator Cuff TearsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 63 participants (actual)
Sponsor and investigators
- Lead sponsor
- Florence Nightingale Hospital, Istanbul
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Celaleddin BILDIK, Florence Nightingale Hospital, Istanbul
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05453266
- Sponsor's protocol ID
- 13.02.2020/009
- Status last verified
- Jul 2022
- First submitted
- 28 Jun 2022
- Last updated
- 12 Jul 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share the IPD.
Study at a glance
From the registry record, last updated by the sponsor on 12 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Arthroscopic Rotator Cuff Repair Performed With Intraarticular Tranexamic Acid. Could it Provide Improved Visual Clarity and Less Post-operative Pain? A Prospective, Double Blind, Randomized Study of 63 Patients
- ClinicalTrials.gov ID
- NCT05453266
- Acronym / sponsor ID
- 13.02.2020/009
- Conditions
- Rotator Cuff Tears, Rotator Cuff Rupture, Tranexamic Acid, Shoulder Arthroscopy, Visual Clarity
- Keywords
- Rotator cuff tear, Rotator cuff rupture, Tranexamic acid, Shoulder arthroscopy, Visual clarity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 63 participants (actual)
- Lead sponsor
- Florence Nightingale Hospital, IstanbulUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 5 Jun 2022 (actual)
- Study completion
- 10 Jun 2022 (actual)
- First posted
- 12 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Shoulder arthroscopy is widely used for treatment of different shoulder pathologies. Visual clarity is essential for successful and safe surgery. The aim of present study is to determine whether intraarticular use of tranexamic acid (TXA) in surgery fluid can improve visual clarity and early postoperative pain.
Detailed description
Patients and Methods After obtaining institutional review board approval (Istanbul Yeni Yuzyil University, Nr: 13.02.2020/009) together with the registry to ClinicalTrials.gov, patients were prospective enrolled in this observational study, which was designed as double-blind, placebo-controlled and randomized.
Inclusion criteria were defined as: being older than 18 years of age, having an MRI confirmed rotator cuff rupture with a history of failure of conservative treatment of at least 6 months, being willing to participate to the clinical trial.
Patient Selection Exclusion criteria were defined as: patients with a history of coagulopathy, deep venous thrombosis, tendency to thrombotic events, patients under anti-coagulant therapy, patients with inferior vena cava filter, patients with abnormal prothrombin time-activated partial thromboplastin time-bleeding time, patients with a history of cardiac/renal/hepatic disease, patients with a diagnosis of TXA allergy, patients with an acute RCT, having been treated conservatively for less than 6 months, being under the age of 18. Table 1.
As a result of the inclusion/exclusion criteria, 42 patients (14 had acute RCT, 12 were receiving anti-coagulant therapy, 9 had history of cardiac/hepatic/renal disease, 5 had abnormal PT-aPTT value at the time of the diagnosis, 2 had received conservative treatments for less than 6 months for RCR) were excluded from 105 patients, who were eligible and were willing to participate. The remaining 63 patients were enrolled in the study. Table 2 (Flowchart). All patients provided informed consents, so that their pre-operative, intra-operative and post-operative data including imaging studies and arthroscopic images could be used for publication by concealing their identity.
Randomization By using computer based randomization software acquired from random.org, patients were randomized into two groups comprising a TXA group (n=32, 24M, 8F) (TXA Group) and a control group (n=31, 22M,9F) (Control Group), while group information was neither shared with patients nor with the operating surgeon as a result of double-blind nature of the study.
Double-blinded preparation of the Irrigation Solutions To conduct a double-blinded, randomized control study, arthroscopic irrigation solutions (normal saline) of 3 liters were prepared by an operating nurse, while 250 mg TXA was injected into irrigation solutions of Group 1, and irrigation solutions of Group 2 were left TXA-free without any injection.
Surgical Procedures All procedures were performed under general anesthesia in beach-chair position by the same surgeon (C.B.) by following the exact same surgical steps in the exact same sequence irrespective of the patient's assignment to TXA group or control group. The surgical procedure comprised thorough evaluation of the glenohumeral joint, together with the rotator interval. In case of a degenerative biceps tendon, a biceps tenotomy was undertaken (TXA Group: 28 patients, Control Group: 26 patients). The repair of supraspinatus tendon was undertaken by utilizing single-row technique. A pressure-controlled pump was used to keep the pressure of the irrigation solution constantly at 50 mmHg. When visibility was decreased as a result of hemorrhage, the pressure was increased by 20 mmHg by using the flush option of the device. During the operation, mean arterial pressure was recorded by the anesthesiologist.
Assessment of Intra-Operative Arthroscopic Visual Clarity and Secondary Outcome Parameters Single surgeon (CB) rated arthroscopic visual score (AVS) similar to the grading system used by van Montfoort21 was used to evaluate intra-operative clarity. AVS was composed of five grades: Grade I: I had no disruption of visual clarity due to bleeding.
Grade II: I had mild disruption of visual clarity due to bleeding. Grade III: I had moderate disruption of visual clarity due to bleeding. Grade IV: I had severe disruption of visual clarity due to bleeding. Grade V: As a result of extreme disruption of visual clarity due to bleeding, I had to convert to open surgery.
AVS score for every patient was calculated as the following: The video of the operation was watched by the operating surgeon (CB) after the surgery and at every 15 minutes, a score of AVS was recorded. At the end, the average score for every single patient was calculated.
Pain was evaluated by using visual analogue scale (VAS) post-operative 8th, 24th and 48th hour.
Patients' mean arterial pressures (MAP) and total duration of operations were recorded.
All of the average aforementioned data of the two groups were compared. Post-operative Patient Management Patients were applied abduction brace after the operation and they were advised to limit the active shoulder range of motion together with abduction during their stay in the hospital.
Pain management was performed by 500 mg paracetamol injection at every 8 hours and intramuscular injection of ketorolac at 24 hours. Patients were discharged at the second post-operative day, when they were confirmed to be stable with tolerable pain.
Statistical method To calculate the sample size, G-Power software (gpower.hhu.de, v 3.1.9.4) was used, while a statistical power (1-ß), alpha error and impact value were calculated as 0.8, 0.05 and 0.8 respectively. As a result of this priori power analysis model, at least 30 speciments were calculated to be required in each group, which was consistent with out design.
For the statistical analysis SPSS software (Version 25.0; SPSS Inc, Chicago, IL, USA) was used. Data are expressed as mean +/- SD (standard deviation). The cohort and the variables were tested for normal distribution and data normality was confirmed by Shapiro-Wilk test. Age, sex, surgery time, mean arterial blood pressure, surgical visaualization score, AVS and postoperative pain scores were compared between groups. Demographic characteristics of the patients were analyzed using descriptive statistics analysis methods, with mean and standard deviation. Normality analysis was made with different methods including histogram, kurtosis and skewness test. Independent sample t-test was used to compare the difference between groups. Analysis of postoperative pain scores at different time points scores within the groups at different time points was made with repeated measures ANOVA test. Results were reported at a 95% confidence interval, and P values <0.05 were considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TXA Group | Active comparator | Procedure: Application of Tranexamic acid in arthroscopic irrigation solutionPatients with rotator cuff tear, operated arthroscopically under intraarticularly applied tranexamic acid in arthroscopic irrigation solution. |
| Control group | Placebo comparator | Procedure: No application of Tranexamic acid in arthroscopic irrigation solutionPatients with rotator cuff tear, operated arthroscopically without intraarticularly applied tranexamic acid in arthroscopic irrigation solution. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- being older than 18 years of age,
- having an MRI confirmed rotator cuff rupture with a history of failure of conservative treatment of at least 6 months,
- being willing to participate to the clinical trial.
Key exclusion criteria (8 listed)
- patients with a history of coagulopathy, deep venous thrombosis, tendency to thrombotic events,
- patients under anti-coagulant therapy,
- patients with inferior vena cava filter,
- patients with abnormal prothrombin time-activated partial thromboplastin time-bleeding time,
- patients with a history of cardiac/renal/hepatic disease,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Application of Tranexamic acid in arthroscopic irrigation solutionApplication of Tranexamic acid in arthroscopic irrigation solution | Procedure or surgery | TXA Group |
| No application of Tranexamic acid in arthroscopic irrigation solutionNo application of Tranexamic acid in arthroscopic irrigation solution | Procedure or surgery | Control group |
Primary outcome
Arthroscopic Visual Clarity
Time frame: Intra-operatively
Effect of TXA in arthroscopic irrigation solution to Arthroscopic Visual Clarity
1 secondary outcome
Post-operative Pain Evaluation
Time frame: Up to the 2nd post-operative day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jul 2022.
- Individual participant dataSharing planned: No. There is no plan to share the IPD.
Related trials for Rotator Cuff Tears
Active, not recruitingPhase 1
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults
Rotator Cuff Tears, Muscle Atrophy or Weakness
Not yet recruiting
Voll Non-Degradable Shoulder Spacer FIH Study
Massive Rotator Cuff Tears, Massive Rotator Cuff Tear
Active, not recruitingPhase 2
Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder
Orthopedics, Traumatology
Recruiting
SMR Stemless Reverse vs SMR Reverse Shoulder System
Arthroplasty, Replacement
Active, not recruiting
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
Rotator Cuff Tears
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Application of Tranexamic acid in arthroscopic irrigation solution and No application of Tranexamic acid in arthroscopic irrigation solution in people with Rotator Cuff Tears and Rotator Cuff Rupture, run by Florence Nightingale Hospital, Istanbul at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arthroscopic Visual Clarity (time frame: Intra-operatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2022.